APR 13, 2021 11:34 AM PDT

New efforts to predict which patients will suffer from side effects from immunotherapy

The findings from a study published in the Journal for ImmunoTherapy of Cancer give medical professionals a way to predict which patients will have serious or life-threatening side effects as a result of immunotherapy. The findings from Massachusetts General Hospital (MGH) researchers will help clinicians decide which cancer patients should receive immunotherapy and which should not take the risk. 

"We found that younger age, melanoma, and kidney cancer were each predictive of the development of severe immunotherapy toxicities," comments co-senior author Yevgeniy R. Semenov, MD, an investigator in the Department of Dermatology at MGH. "Understanding the risk factors for predicting high-grade toxicities will help in appropriately selecting patients most likely to tolerate immune checkpoint inhibitor therapy. It will also help to identify higher risk patients who should be carefully monitored if they initiate this therapy."

The researchers add that additionally patients who received multiple immune checkpoint inhibitors instead of a single type also had more toxic immune reactions. Watch the video below to learn more about how these therapies work.

In conducting their investigation, the team analyzed data from 14,378 patients with cancer who received immune checkpoint inhibitors in the United States between 2011 and 2019. Of that population, 3.5% had serious side effects that required hospitalization and immunosuppression treatments. 

"This study provides the foundation for studying severe immunotherapy toxicities using a Big Data analytic framework, which will be necessary when understanding the impact of these life-saving medications across diverse populations," says Semenov. "Also, it is the first step in developing robust clinical risk prediction models to identify patients at highest risk for the development of life-threatening treatment complications."

Sources: Journal for ImmunoTherapy of Cancer, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUN 22, 2021
Cancer
Evaluating adverse effects of induction therapy for neuroblastoma
JUN 22, 2021
Evaluating adverse effects of induction therapy for neuroblastoma
A study published in the Journal of Clinical Oncology reports an evaluation of the chemotherapy treatment given to child ...
JUL 13, 2021
Clinical & Molecular DX
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
JUL 13, 2021
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
Researchers have developed the first diagnostic “pen” that acts as a guide for surgeons, helping them distin ...
AUG 13, 2021
Cancer
Ultrasound Triggers Immunotherapy to Destroy Tumors
AUG 13, 2021
Ultrasound Triggers Immunotherapy to Destroy Tumors
An immunotherapy engineered to be triggered by ultrasound beams significantly slows the growth of cancerous tumors in mi ...
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
SEP 06, 2021
Cancer
A New Biomarker to Personalize Breast Cancer Therapy
SEP 06, 2021
A New Biomarker to Personalize Breast Cancer Therapy
The American Cancer Society estimates that over 280,000 women in the United States will be diagnosed with breast cancer ...
SEP 20, 2021
Cancer
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
SEP 20, 2021
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
For the past several decades, cancer antigen 125 (CA 125), a protein located on the surface of ovarian cancer cells, has ...
Loading Comments...